Harvard Bioscience (NASDAQ:HBIO) Stock Price Crosses Below 200-Day Moving Average of $4.07

Harvard Bioscience, Inc. (NASDAQ:HBIO) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.07 and traded as low as $2.77. Harvard Bioscience shares last traded at $2.79, with a volume of 56,748 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, May 9th.

Harvard Bioscience Stock Performance

The company has a market capitalization of $121.17 million, a price-to-earnings ratio of -13.95 and a beta of 1.31. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.94 and a current ratio of 1.88. The company’s fifty day simple moving average is $3.23 and its two-hundred day simple moving average is $4.07.

Insiders Place Their Bets

In related news, CEO James W. Green acquired 10,000 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was bought at an average cost of $2.91 per share, with a total value of $29,100.00. Following the acquisition, the chief executive officer now directly owns 3,111,091 shares in the company, valued at $9,053,274.81. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Harvard Bioscience news, CEO James W. Green purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was acquired at an average cost of $3.07 per share, with a total value of $61,400.00. Following the acquisition, the chief executive officer now owns 3,101,091 shares of the company’s stock, valued at approximately $9,520,349.37. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO James W. Green purchased 10,000 shares of the firm’s stock in a transaction dated Thursday, June 13th. The stock was acquired at an average cost of $2.91 per share, with a total value of $29,100.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,111,091 shares in the company, valued at approximately $9,053,274.81. The disclosure for this purchase can be found here. 9.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HBIO. New York State Common Retirement Fund lifted its position in Harvard Bioscience by 3.2% in the 4th quarter. New York State Common Retirement Fund now owns 142,460 shares of the medical instruments supplier’s stock valued at $762,000 after purchasing an additional 4,463 shares during the last quarter. Bailard Inc. bought a new stake in Harvard Bioscience in the 4th quarter valued at about $106,000. Acuitas Investments LLC lifted its position in Harvard Bioscience by 35.0% in the 4th quarter. Acuitas Investments LLC now owns 326,516 shares of the medical instruments supplier’s stock valued at $1,747,000 after purchasing an additional 84,735 shares during the last quarter. AMH Equity Ltd lifted its position in Harvard Bioscience by 1.0% in the 4th quarter. AMH Equity Ltd now owns 2,162,893 shares of the medical instruments supplier’s stock valued at $11,571,000 after purchasing an additional 21,540 shares during the last quarter. Finally, Corsair Capital Management L.P. bought a new stake in Harvard Bioscience in the 4th quarter valued at about $356,000. 80.87% of the stock is owned by institutional investors and hedge funds.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.